title: Pharmacokinetics of clindamycin in pregnant women in the peripartum period.
abstract: The study presented here was performed to determine the pharmacokinetics of intravenously administered clindamycin in pregnant women. Seven pregnant women treated with clindamycin were recruited. Maternal blood and arterial and venous umbilical cord blood samples were obtained. Maternal clindamycin concentrations were analyzed by nonlinear mixed-effects modeling with the NONMEM program. The data were best described by a linear three-compartment model. The clearance and the volume of distribution at steady state were 10.0 liters/h and 6.32 x 10(3) liters, respectively. Monte Carlo simulations were performed to determine the area under the concentration curve (AUC) for the free (unbound) drug (f) in maternal serum for 24 h divided by the MIC (fAUC(0-24)/MIC). At a MIC of 0.5 mg/liter, which is the EUCAST breakpoint, the attainment at the lower 95% confidence interval (CI) was 24.6 if the level of protein binding was 65%, and this value concurred well with the target value of 27. However, for higher degrees of protein binding, as has been described in the literature, the attainment was lower, down to 10.2 for a protein binding level of 85% (lower 95% CI). The concentrations in umbilical cord blood were lower than those in maternal blood. The concentration-time profiles in maternal serum indicate that the level of exposure to clindamycin may be too low in these patients. Together with the lower concentrations in umbilical cord blood, this finding suggests that the current dosing regimen may not be adequate to protect all neonates from group B streptococcal disease.
authors.affiliation: Medical Centre Haaglanden (MCH), Department of Obstetrics and Gynecology, The Hague, Netherlands. muller.research@Gmail.com
authors.forename: Anouk E
authors.initials: AE
authors.lastname: Muller
authors.forename: Johan W
authors.initials: JW
authors.lastname: Mouton
authors.forename: Paul M
authors.initials: PM
authors.lastname: Oostvogel
authors.forename: P Joep
authors.initials: PJ
authors.lastname: Dörr
authors.forename: Rob A
authors.initials: RA
authors.lastname: Voskuyl
authors.forename: Joost
authors.initials: J
authors.lastname: DeJongh
authors.forename: Eric A P
authors.initials: EA
authors.lastname: Steegers
authors.forename: Meindert
authors.initials: M
authors.lastname: Danhof
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D002981:Clindamycin / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D005260:Female; D005312:Fetal Blood; D006801:Humans; D007262:Infusions, Intravenous; D008954:Models, Biological; D009010:Monte Carlo Method; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy* / Q000517:prevention & control; D013290:Streptococcal Infections / Q000188:drug therapy* / Q000517:prevention & control; D013292:Streptococcus agalactiae / Q000187:drug effects*; D014469:Umbilical Arteries; D014471:Umbilical Veins
chemical_list: D000900:Anti-Bacterial Agents; D002981:Clindamycin